There are currently 415 clinical trials in Las Vegas, Nevada looking for participants to engage in research studies. Trials are conducted at various facilities, including Comprehensive Cancer Centers of Nevada, University Medical Center of Southern Nevada, Summerlin Hospital Medical Center and Alliance for Childhood Diseases/Cure 4 the Kids Foundation. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
NCT00358943
Recruiting
The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The objectives of the Registry are: * To enhance understanding of the variability, progression, identification, and natural... Read More
Gender:
ALL
Ages:
All
Trial Updated:
11/19/2024
Locations: Children's Specialty Center of Nevada- Site Number : 840008, Las Vegas, Nevada
Conditions: Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease
Register for Updates
MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
NCT05464784
Recruiting
The design of the Phase 2 clinical trial includes the following elements: * Multi-center, two-arm, randomized, double-blind, placebo-controlled trial to evaluate MN-001 (tipelukast) vs. placebo in approximately 40 patients in the U.S. * Patients will be randomized 1:1 to receive either 500 mg/day of MN-001 (tipelukast) or placebo for 24 weeks. * The co-primary endpoints are (1) change from baseline in liver fat content measured by controlled attenuation parameter (CAP) score at Week 24, and (2)... Read More
Gender:
ALL
Ages:
Between 21 years and 75 years
Trial Updated:
11/18/2024
Locations: Jubilee Clinical Research, Inc., Las Vegas, Nevada
Conditions: Diabetes Mellitus, Type 2, Hypertriglyceridemia, Non-Alcoholic Fatty Liver Disease
Register for Updates
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
NCT02854033
Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's diseas... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
11/18/2024
Locations: Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada
Conditions: Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
Register for Updates
Safety and Efficacy of ActiGraft Treatment in Wound Care in Medical Centers
NCT04699305
Recruiting
Multicenter observational study to explore the efficacy of ActiGraft in the treatment of exuding cutaneous wounds in real-life usage.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: Wound Care Experts, Las Vegas, Nevada
Conditions: Cutaneous Wounds
Register for Updates
Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism
NCT06531941
Recruiting
The purpose of this study is to evaluate the long-term safety and tolerability of MBX 2109 in patients with hypoparathyroidism who completed the 12-week treatment period in the Phase 2 study, MBX-2H1002.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
11/11/2024
Locations: MBX Biosciences Investigational Site, Las Vegas, Nevada
Conditions: Hypoparathyroidism
Register for Updates
Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)
NCT04315324
Recruiting
This phase II trial studies how well OBI-3424 works in treating patients with T-cell acute lymphoblastic leukemia that has come back (relapsed) or does not response to treatment (refractory). Drugs used in chemotherapy, such as OBI-3424, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. OBI-3424 may reduce the amount of leukemia in the body.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/05/2024
Locations: Las Vegas Urology - Pecos, Las Vegas, Nevada +33 locations
Conditions: Recurrent T Acute Lymphoblastic Leukemia, Refractory T Acute Lymphoblastic Leukemia
Register for Updates
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body
NCT04248452
Recruiting
This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a limited number of other places in the body (oligometastatic disease). Radiotherapy uses high energy x-rays, gamma rays, or protons to kill tumor cells and shrink tumors. Drugs used in usual chemotherapy, such as leucovorin, 5-fluorouracil, oxaliplatin, and capecitabine, wor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: Las Vegas Urology - Pecos, Las Vegas, Nevada +35 locations
Conditions: Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Oligometastatic Esophageal Adenocarcinoma, Oligometastatic Gastric Adenocarcinoma, Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8
Register for Updates
Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study
NCT06312722
Recruiting
The goal of this clinical trial is to verify the continued safety and effectiveness for the Optilume BPH Catheter System.
Gender:
MALE
Ages:
50 years and above
Trial Updated:
11/04/2024
Locations: Sheldon Freedman MD, Ltd, Las Vegas, Nevada
Conditions: Benign Prostatic Hyperplasia
Register for Updates
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
NCT05108298
Recruiting
The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
10/28/2024
Locations: Las Vegas Urology - Pecos, Las Vegas, Nevada +29 locations
Conditions: Breast Cancer, NOS, CNS Primary Tumor, NOS, Cervical Cancer, NOS, Colorectal Cancer, NOS, Leukemia, NOS, Lymphoma, NOS, Miscellaneous Neoplasm, NOS, Non-Rhabdomyosarcoma Soft Tissue Sarcoma, NOS, Testicular Nonseminomatous Germ Cell Tumor, NOS, Thyroid Cancer, NOS, Melanoma, Bone Cancer, NOS
Register for Updates
ALTO-100 in Bipolar Disorder with Depression (BD-D)
NCT06656416
Recruiting
The purpose of this study is to assess antidepressant efficacy differences between ALTO-100 and placebo during the Double-Blind period in patients with bipolar disorder I or II with current major depressive episode, when used adjunctively to a mood stabilizer, related to patient characteristics. Additionally, safety, tolerability, and efficacy will be assessed in a subsequent open label treatment period.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
10/22/2024
Locations: Site 6144, Las Vegas, Nevada
Conditions: Bipolar Disorder I or II with a Major Depressive Episode
Register for Updates
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
NCT06002828
Recruiting
This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer experience different diagnoses and specific biological, clinical, psychological and social factors that affect their risks for post-treatment morbidity and premature death. Collecting samples of blood samples and health and treatment information from cancer sur... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/18/2024
Locations: Las Vegas Urology - Pecos, Las Vegas, Nevada +27 locations
Conditions: Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Register for Updates
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
NCT05566769
Recruiting
NMOSDCopilot is a digital tool developed for the self-assessment of Neuromyelitis Optica Spectrum Disorder symptoms that impact patients' functioning and quality of life. It has been co-designed with the help of patient advocacy groups, NMOSD patients and medical experts. It includes a smartphone-based application for patients, connected to a web portal developed for healthcare professionals (HCSPs). The patient application is composed of vision, walking, cognition, and dexterity e-active tests... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/14/2024
Locations: CC Lou Ruvo Center for Brain Health, Las Vegas, Nevada
Conditions: Neuromyelitis Optica
Register for Updates